Straits Times Index
3,410.81 -29.07 (-0.85%) S&P 500
5,567.19 +30.17 (+0.54%) Dow
39,375.87 +67.87 (+0.17%) Nasdaq
18,352.76 +164.46 (+0.90%) Bitcoin USD
55,628.55 -2,450.06 (-4.22%) CMC Crypto 200
1,158.92 -49.77 (-4.12%)
Becton, Dickinson and Company (BDX.MX)
| Previous close | 4,182.80 |
| Open | 0.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 4,182.80 - 4,182.80 |
| 52-week range | 3,764.15 - 4,843.41 |
| Volume | |
| Avg. volume | 107 |
| Market cap | 1.209T |
| Beta (5Y monthly) | 0.44 |
| PE ratio (TTM) | 49.51 |
| EPS (TTM) | 84.49 |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | 70.08 (1.68%) |
| Ex-dividend date | 10 Jun 2024 |
| 1y target est | N/A |
ZacksThree Reasons to Hold BD (BDX) Stock in Your Portfolio Now
BD's (BDX) robust product portfolio raises optimism about the stock.
PR NewswireBD to Announce Financial Results for its Third Quarter of Fiscal 2024
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will report financial results for its third quarter of fiscal year 2024 on Thursday, August 1, 2024. A news release will be issued at approximately 6:30 a.m. Eastern Time (ET) and will be available at www.bd.com/investors, along with related presentation materials. The news release and presentation materials will include summary financial information for the company's third quarte
PR NewswireNew BD Research Tool Helps Scientists Study Cells that are Often Key Culprits in the Development of Cancer and Infectious Diseases
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the commercial launch of a new single-cell research tool to help scientists better understand how the molecular machinery within a cell functions and how it regulates changes in a cell that can lead to cancer and other diseases.
